In December 2025, CMS announced the Medicare GLP-1 Bridge demonstration, a short-term program that will allow eligible Medicare beneficiaries to access GLP-1 obesity medications at a $50/month co-pay starting July 2026 , using a centralized processor to manage PA, claims adjudication, and payment ( [18] )
A Message on Our Packaging Caring about our health includes the health of the planet and we are constantly striving toward total sustainability
Who Should Use This Product: This product is intended for adults who require higher-potency, targeted support for joint health, digestive function, and gut-brain axis balance, particularly when lower gastrointestinal support is needed
Because it works at a cellular level, BPC-157 supports long-term tissue repair and can be a great option for individuals with chronic injuries or those who live an active lifestyle